S&P Upgrades Kite Realty Group Trust’s Rating Outlook to ‘Positive’ from ‘Stable’
INDIANAPOLIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Kite Realty Group Trust (NYSE: KRG) announced today that S&P Ratings (“S&P”) revised...
Read moreDetails
Panbela Announces Issuance of New Patent in China for Claims of a Novel Process for the Production of SBP-101
Patent developed in collaboration with Syngene International Ltd.MINNEAPOLIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: PBLA), a clinical-stage biopharmaceutical company...
Read moreDetailsKULR and Forge Nano Form a Strategic Partnership for Enhanced Battery Safety and Performance
A Partnership Estimated at $3.5 Million to $5 Million Incorporates KULR ONE Design Solutions with Forge Nano’s Battery Cells SAN...
Read moreDetailsBlink Charging Teams Up with Parkopedia to Provide EV Drivers Greater Accessibility to Electric Vehicle Charging
Integration of nearly 12,000 Blink public charging stations across the U.S. to Parkopedia’s parking services has already begun. Miami Beach,...
Read moreDetailsurban-gro, Inc. Awarded Contract for More Than $11 Million of Design-Build Services with Existing Client in the Hospitality & Recreation Sector
LAFAYETTE, Colo., Sept. 26, 2023 (GLOBE NEWSWIRE) -- urban-gro, Inc. (Nasdaq: UGRO) (“urban-gro” or the “Company”), an integrated professional services...
Read moreDetailsiRhythm Launches Next Generation Zio Monitor and Enhanced Zio Service: Its Smallest, Lightest and Thinnest Cardiac Monitor
Zio monitor Zio monitor by iRhythm iRhythm is launching its next generation long-term ambulatory cardiac monitor in the U.S.Zio® monitor...
Read moreDetailsSonochemical Coatings Market Predicted to Reach US$ 6 Billion in Revenues by 2031: Report from TMR
New treatments and increasing drug development are expected to drive market growth. Pharma drug development and government investments will drive...
Read moreDetailsPhathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
Submission based on positive results from Phase 3 PHALCON-NERD-301 in which vonoprazan 10 mg and 20 mg controlled heartburn symptoms...
Read moreDetailsPaytronix Annual Loyalty Report 2023: Loyalty Membership & Revenue Grow as Program Costs Decline
Paytronix Loyalty Report: 2023 Paytronix Annual Loyalty Report 2023: Loyalty Membership & Revenue Grow as Program Costs Decline Convenience Store...
Read moreDetailsTaysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome
Available clinical data from the two adult patients dosed with TSHA-102 in the first cohort (low dose) to be discussed...
Read moreDetailsADVERTISEMENTS
